"As an emerging leader in melanocortin research, we now have the opportunity with Synacthen to expand and accelerate our product development activities. We believe such efforts will enhance our ...

Hormonal insufficiency of the hypothalamic–pituitary–adrenal (HPA) axis is a common complication in patients who have undergone pituitary surgery. Different procedures are used to assess HPA function ...

Injecting performance enhancing corticosteroid hormones for other than medical treatment is banned, and tests exist that can detect injected hormones. Injecting synacthen, which stimulates the body to ...

Until now there has been no test that could detect synacthen, which when injected simulates the body to produce extra amounts of its own corticosteroid. This is most common in sports where sports ...

Mallinckrodt announced that the FDA has granted Fast Track designation to the Investigational New Drug (IND) application of Synacthen Depot (tetracosactide) for the treatment of Duchenne muscular ...

Mallinckrodt plc (NYSE: MNK) revealed Monday that it submitted an Investigational New Drug (IND) application for Synacthen Depot to the U.S. Food and Drug Administration (FDA). The company indicated ...

Why try to beat 'em if you can just buy 'em? That's the approach that Questcor Pharmaceuticals is taking. The biotech announced today that it has acquired rights to develop Syncathen and Synacthen ...